Evidence map›Paper›PMID 41714840›Full record

ArticleEmerging infectious diseases2026

Effectiveness of RSV Vaccines against RSV-Associated Thromboembolic Events.

Ryan E Wiegand, Heng-Ming Sung, Yue Zhang, Andrea Chavez, Amber Kautz, Josephine Mak, Morgan Najdowski, Yangping Chen, Yenlin Lai, Yixin Jiao and 3 more

Abstract read
In one paragraph

Article in Emerging infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ryan E Wiegand
Heng-Ming Sung
Yue Zhang
Andrea Chavez
Amber Kautz
Josephine Mak
Morgan Najdowski
Yangping Chen
Yenlin Lai
Yixin Jiao
Yoganand Chillarige
Ruth Link-Gelles
Amanda B Payne

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We evaluated effectiveness of respiratory syncytial virus (RSV) vaccines against RSV-associated thromboembolic events among community-dwelling Medicare fee-for-service beneficiaries >65 years of age in the United States enrolled during October 1, 2023-March 30, 2024. RSV vaccines protected against RSV-associated thromboembolic events (effectiveness 79% [95% CI 74%-83%]) in the same season as vaccine receipt.

Indexed as

Respiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesThromboembolismVaccine EfficacyAgedAged, 80 and overFemaleHumansMaleUnited StatesRespiratory Syncytial Virus Vaccinesrespiratory syncytial virusthromboembolismUnited Statesvaccine effectivenessvaccine-preventable diseasesviruses

Identifiers

PMID41714840
PMCPMC12928231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.